Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

XBI Guru Trades in

XBI Guru Trades in

XBI Guru Trades in

Q1 2016

XBI Guru Trades in Q1 2016

First Eagle Investment 18,150 sh (New)
» More

Ratios

vs
industry
vs
history
P/B 4.68
XBI's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 4.68 )
Ranked among companies with meaningful P/B only.
XBI' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 4.6
Current: 4.68
0
4.6

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
XBI's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.50 )
Ranked among companies with meaningful Dividend Yield only.
XBI' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.51
Current: 0.5
0
0.51
Yield on cost (5-Year) 0.51
XBI's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.51 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XBI' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.51
Current: 0.51
0
0.51

More Statistics

Short Percentage of Float0.00%
52-Week Range $45.73 - 218.67
Shares Outstanding (Mil)37,100,000.00
» More Articles for XBI

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Viacom Inc. Jul 27 2016 
Mario Gabelli Comments on Sony Corp Jul 27 2016 
Mario Gabelli Comments on Ryman Hospitality Properties Inc. Jul 27 2016 
Mario Gabelli Comments on Newmont Mining Corp Jul 27 2016 
Mario Gabelli Comments on Honeywell International Inc. Jul 27 2016 
Mario Gabelli Comments on Edgewell Personal Care Co. Jul 27 2016 
Mario Gabelli Comments on DISH Network Corp Jul 27 2016 
Mario Gabelli Comments on CBS Corp Jul 27 2016 
Equity Market Highs, Bond Yields at Record Lows. Who's Right? Jul 27 2016 
Daniel Loeb's Third Point 2nd-Quarter 2016 Investor Letter Jul 27 2016 

More From Other Websites
Yee: Biotech stocks will outperform after election Jul 25 2016
Bracing for a 'bio-wreck'? Jul 25 2016
This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles Jul 25 2016
Will Orenitram Lose Market Share to Uptravi in 2016? Jul 22 2016
Is biotech back? Jul 21 2016
How Much Potential Does Promacta Hold? Jul 18 2016
Ligand Pharmaceuticals’s Performance Based on EV-to-EBITDA Jul 14 2016
ALNY Reports Positive Results from Open Label Extension Study of Revusiran Jul 14 2016
New Stock Market Highs Fighting Many More Outside Pressures Than Usual: Time to Panic? Jul 13 2016
Strong ISM Non-Manufacturing PMI Overshadows Services PMI Jul 07 2016
AbbVie’s Tests of Imbruvica with Venclexta for Oncology Therapy Jul 05 2016
Biotech Bottom Calls After Big Bounce (IBB, XBI) Jul 01 2016
What Are the Benefits of the Novartis-Xencor Alliance to Xencor? Jul 01 2016
Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here Jul 01 2016
Biotechs Building Base?...Or Bursting Bubble? Jun 30 2016
How Did Investors Respond to the Novartis-Xencor Alliance? Jun 30 2016
The Novartis-Xencor Collaboration Agreement: The Details Jun 30 2016
Hedge Funds Like ETFs Too Jun 30 2016
US Inflation Numbers Are Decent, Brexit Clouds Future Outlook Jun 30 2016
US GDP and Consumer Confidence: Is a Revival Coming? Jun 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK